Ed Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer mitomycin-C in ab externo glaucoma surgery. Mitosol avoids the issues of sterility and stability of mitomycin-C made in compounding pharmacies. Mobius is investigating the use of the platform in refractive surgery.
Ed has more than 25 years experience in the surgical device/life science industry. He has initiated and/or grown sub-specialty franchises for multiple companies, to include American Hospital Supply Corporation, Applied Medical Resources, Storz Ophthalmics, and Given Imaging, Ltd.